AB1241 MOST PREVALENT COMORBIDITIES IN PRIMARY SJÖGREN’S SYNDROME IN A HISPANIC POPULATION
Authors: Nicolás Alfaro, Janett Carmen Riegatorres, Gabriela Hernandez-Molina, Rosa-Elda Barbosa-Cobos, Ana Cecilia Arana Guajardo, Mario Alberto Garza Elizondo, Dionicio Ángel Galarza-Delgado, Cassandra Michele Skinner Taylor, Amaya Llorente-Chavez, Cesar Vidal Solis
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Comorbidities are an important issue to consider in patients with rheumatic diseases (RD), as well as the clinical assessment of the autoimmune disease. Looking for concomitant diseases is a necessary step for a global approach of the rheumatic patient, knowingly that some diseases are more frequent in patients with RD than in the general population and could influence the course of RD and achievement of treatment goals<sup>1</sup>. Despite this, there is a need of new evidence about primary Sjögren's Syndrome (pSS) comorbidities and their association with clinical outcomes. <h3>Objectives</h3> To determine the prevalence of comorbidities in patients with pSS in mexican population. <h3>Methods</h3> This was a national, multicenter, cross-sectional, and observational study. We included 393 patients with pSS, diagnosed according to the American-European Consensus Group (AECG) criteria 2002 or ACR/EULAR 2012 criteria. Comorbidities, serological profile of autoantibodies, Schirmer's test, sialometry and histopathological assessment from minor salivary gland biopsies reported in the medical records were evaluated by a rheumatologist. The comparisons between the study groups were carried out using the two-tailed Student's t test, χ2 test, and unidirectional. A value of p&lt;0.05 was considered statistically significant. <h3>Results</h3> At least one comorbidity were reported in 310 (78.9%) patients, 2 to 4 comorbidities were reported in 183 (46.6%), and only 18 (4.6%) had a least 5 comorbidities. Thyroid disease was the most frequent comorbidity, observed in 91 (23.2%) subjects, being hypothyroidism the main cause. Smoking (21.9%) and hypertension (19.6%) were in second and third place. Psychiatric disease was present in 62 (15.8%) patients being depression and anxiety disorders the most frequent, appearing in 49 (79%) and 12 (19.35%) patients respectively. Regarding malignancy, we documented 10 (2.5%) patients with lymphoma, and 4 (1%) patients with breast cancer. The rest of comorbidities are shown at Figure 1 and Table 1. There was no significant difference for each variable measured between the groups except for the mean age (p= 0.001). <h3>Conclusion</h3> The systematic evaluation of comorbidities in patients with pSS is essential for an integral management. Physicians should be aware that these conditions might directly impact quality of life, prognosis, treatment response and healthcare costs. We encourage further research for the identification of new approaches in benefit of the patients. <h3>References</h3> [1] Yurkovich, et al. (2014). Overall and Cause-Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta-Analysis of Observational Studies. Arthritis Care &amp; Research, 66(4), 608–616. https://doi.org/10.1002/acr.22173. <h3>Disclosure of Interests</h3> None declared